DL
Therapeutic Areas
Soligenix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SGX301 | Cutaneous T-Cell Lymphoma (CTCL) | Phase 3 |
| SGX942 | Oral Mucositis in Head & Neck Cancer | Phase 3 |
| SGX945 | Behçet's Disease (Oral Ulcers) | Phase 2a |
| SGX302 | Psoriasis (Plaque) | Phase 2a |
| RiVax® | Prevention of Ricin Intoxication | Phase 1b |
| SGX204 | Filovirus (Ebola/Marburg) Vaccine | Preclinical |
| Dengue Vaccine | Prevention of Dengue Fever | Preclinical |
Leadership Team at Soligenix
CJ
Christopher J. Schaber, PhD
President, Chief Executive Officer, Director
JL
Jonathan L. Guarino, CPA
Chief Financial Officer
OD
Oreola Donini, PhD
Senior Vice President, Chief Scientific Officer
RS
Richard Straube, MD
Senior Vice President, Chief Medical Officer